Metabolomics Market Report 2025

This Metabolomics market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The metabolomics market size has grown rapidly in recent years. It will grow from $3.62 billion in 2024 to $4.18 billion in 2025 at a compound annual growth rate (CAGR) of 15.4%. The growth in the historic period can be attributed to advancements in healthcare, drug discovery and development, disease biomarker identification, academic and research institutions, nutrition and food science.

The metabolomics market size is expected to see rapid growth in the next few years. It will grow to $7.99 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to personalized healthcare, drug safety and efficacy, microbiome and gut health, environmental and agricultural applications, regenerative medicine. Major trends in the forecast period include integration with other omics, targeted metabolomics, single-cell metabolomics, data analytics and ai, point-of-care testing.

The increasing incidence of cancer is a primary driver of growth within the metabolomics market. Metabolomics, which scrutinizes potential biomarkers to assess cancer drug responsiveness, plays a vital role in early cancer diagnosis. For instance, in 2023, according to the American Cancer Society, a US-based professional organization, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States, marking an increase from the previous year. Metabolomics methodologies, including nuclear magnetic resonance (NMR) and mass spectrometry (MS) techniques, are pivotal in studying cancer. Companies like Metabolon Inc. and Bruker Corp. have integrated metabolomics to aid in early cancer detection and treatment.

The rising prevalence of chronic diseases is poised to drive the metabolomics market's growth in the foreseeable future. Chronic ailments persist for a year or longer, necessitating ongoing medical intervention and often hindering daily activities. Metabolomics plays a crucial role in uncovering the metabolic underpinnings of chronic diseases, identifying pertinent biomarkers, and pinpointing potential targets for alternative therapies. Its ability to directly connect with an organism's phenotype makes it an invaluable tool in disease and health research. As highlighted in a March 2022 report by the Australian Bureau of Statistics, nearly three-quarters of Australians (78.6%) reported at least one long-term health issue, with almost half of the population (46.6% or 11.6 million individuals) affected by chronic conditions. Hence, the increasing prevalence of chronic diseases is a driving force behind the expansion of the metabolomics market.

The integration of machine learning is increasingly popular within the metabolomics field, significantly enhancing the efficiency of interpreting data obtained from metabolomics techniques. Machine learning-powered technologies automate complex and risky processes, streamline tasks, and offer swift, error-free services. Industry companies are favoring machine learning techniques for metabolism analysis, solving problems, and executing tasks. Various machine learning algorithms aid in metabolism data analysis and modeling metabolic pathways. Companies like Bio-Rad Laboratories, Metabolon Inc., among others, are leveraging machine learning algorithms to enhance understanding and prediction in metabolomics research. For example, MeltDB 2.0, a machine learning software utilized for metabolomics experiment data analysis and integration, provides robust research support, storing experimental datasets, and comprehensive analysis and visualization features to represent large and complex data effectively.

Major companies operating in the metabolomics market are focusing on introducing Integrated Bioinformatics Platforms to enhance the interpretation of complex metabolomic data, supporting advancements in personalized medicine, biomarker discovery, and disease understanding. An Integrated Bioinformatics Platform is a comprehensive software solution that combines various bioinformatics tools and databases, facilitating the analysis and interpretation of biological data. Researchers can map metabolomics data against precise biochemical pathway maps, helping to uncover biological processes and disease mechanisms. For instance, in February 2024, Metabolon, Inc., a US-based company, launched its bioinformatics platform. The "Biomarker Lenses" feature in the Integrated Bioinformatics Platform allows users to apply advanced analytical filters, focusing on metabolites linked to specific pathways or diseases, enabling targeted exploration of metabolomic data. The platform also includes tools for conducting statistical analyses like T-tests and ANOVAs, allowing researchers to build and compare statistical models, manage metadata, and visualize results effectively.

In October 2022, Clinical Microbiomics, a Denmark-based microbiome research company, acquired MS-Omics, a Denmark-based metabolomics company, for an undisclosed sum. This acquisition bolstered Clinical Microbiomics' portfolio by adding specialized metabolic profiling offerings. The addition of MS-Omics' capabilities is set to advance Clinical Microbiomics' systems biology platform, benefiting researchers globally.

Metabolomics is the scientific study of small molecules known as metabolites, which are produced during metabolism within cells, tissues, or organisms. By analyzing and quantifying these metabolites, metabolomics provides valuable insights into biological processes, disease mechanisms, and metabolic pathways. This field plays a critical role in personalized medicine, drug discovery, and understanding the mechanisms of diseases such as cancer and diabetes.

The key products and services in the field of metabolomics encompass metabolomics instruments, metabolomics bioinformatics tools, and various services. Metabolomics instruments are specialized devices employed to comprehensively analyze low-molecular-weight compounds within biological samples. These instruments include separation techniques, detection methodologies, and metabolomics bioinformatics tools and services, which involve databases and bioinformatics tools. Metabolomics finds application in diverse medical indications such as cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and others. These applications are utilized for purposes such as biomarker discovery, drug discovery, toxicology testing, nutrigenomics, functional genomics, personalized medicine, and more.

The metabolomics market research report is one of a series of new reports that provides metabolomics market statistics, including metabolomics industry global market size, regional shares, competitors with a metabolomics market share, detailed metabolomics market segments, market trends and opportunities, and any further data you may need to thrive in the metabolomics industry. This metabolomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Major companies operating in the metabolomics market include Human Metabolome Technologies Inc., Metabolon Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Agilent Technologies Inc., Thermo Fisher Scientific Inc., Waters Corporation, Biocrates Life Sciences AG, Shimadzu Corporation, Danaher Corporation, Kore Technologies Ltd., Dani Instruments SpA, Perkinelmer Inc., Evans Analytical Group LLC, LECO Corporation, Phenomenome Discoveries Inc., AB Sciex, BG Medicine Inc., Biomark Diagnostics Inc., Chenomx Inc., Creative Proteomics, Evotec A.G, Merck kgaA, Southern Research Company Inc., Alcami Corporation, Charles River Laboratories International Inc., Eremid Genomic Services LLC, Metabowerke GmbH, Metabolomic Diagnostics, Phenomenex Inc.

North America was the largest region in the metabolomics market in 2024. Western Europe was the second largest region in the metabolomics market. The regions covered in the metabolomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the metabolomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The metabolomics market includes revenue earned by liquid chromatography, gas chromatography, capillary electrophoresis, mass spectrometry, and nuclear magnetic resonance spectroscopy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.